Convection-enhanced delivery of M13 bacteriophage to the brain
Laboratory investigation
Search for other papers by Alexander Ksendzovsky in
Current site
Google Scholar
PubMed
Search for other papers by Stuart Walbridge in
Current site
Google Scholar
PubMed
Search for other papers by Richard C. Saunders in
Current site
Google Scholar
PubMed
Search for other papers by Ashok R. Asthagiri in
Current site
Google Scholar
PubMed
Search for other papers by John D. Heiss in
Current site
Google Scholar
PubMed
Search for other papers by Russell R. Lonser in
Current site
Google Scholar
PubMed
Object
Recent studies indicate that M13 bacteriophage, a very large nanoparticle, binds to β-amyloid and α-synuclein proteins, leading to plaque disaggregation in models of Alzheimer and Parkinson disease. To determine the feasibility, safety, and characteristics of convection-enhanced delivery (CED) of M13 bacteriophage to the brain, the authors perfused primate brains with bacteriophage.
Methods
Four nonhuman primates underwent CED of M13 bacteriophage (900 nm) to thalamic gray matter (4 infusions) and frontal white matter (3 infusions). Bacteriophage was coinfused with Gd-DTPA (1 mM), and serial MRI studies were performed during infusion. Animals were monitored for neurological deficits and were killed 3 days after infusion. Tissues were analyzed for bacteriophage distribution.
Results
Real-time T1-weighted MRI studies of coinfused Gd-DTPA during infusion demonstrated a discrete region of perfusion in both thalamic gray and frontal white matter. An MRI-volumetric analysis revealed that the mean volume of distribution (Vd) to volume of infusion (Vi) ratio of M13 bacteriophage was 2.3 ± 0.2 in gray matter and 1.9 ± 0.3 in white matter. The mean values are expressed ± SD. Immunohistochemical analysis demonstrated mean Vd:Vi ratios of 2.9 ± 0.2 in gray matter and 2.1 ± 0.3 in white matter. The Gd-DTPA accurately tracked M13 bacteriophage distribution (the mean difference between imaging and actual bacteriophage Vd was insignificant [p > 0.05], and was –2.2% ± 9.9% in thalamic gray matter and 9.1% ± 9.5% in frontal white matter). Immunohistochemical analysis revealed evidence of additional spread from the initial delivery site in white matter (mean Vd:Vi, 16.1 ± 9.1). All animals remained neurologically intact after infusion during the observation period, and histological studies revealed no evidence of toxicity.
Conclusions
The CED method can be used successfully and safely to distribute M13 bacteriophage in the brain. Furthermore, additional white matter spread after infusion cessation enhances distribution of this large nanoparticle. Real-time MRI studies of coinfused Gd-DTPA (1 mM) can be used for accurate tracking of distribution during infusion of M13 bacteriophage.
Abbreviations used in this paper:
AAV = adenoma-associated virus; AD = Alzheimer disease; CED = convection-enhanced delivery; PBS = phosphate-buffered saline; PD = Parkinson disease; Vd = volume of distribution; Vi = volume of infusion.
© Copyright 1944-2023 American Association of Neurological Surgeons